This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Board to approve September quarter and nine-month results
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board will meet on 28 October 2026 to approve unaudited financial results for the quarter and nine months ended 30 September 2026. The company trading window remains closed from 1 October to 30 October 2026.
No financial figures or performance signals are disclosed yet. Investor reaction will depend on the results approved on 28 October.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹263.1 Cr | ₹233.9 Cr | +12.5% |
| Operating profit | ₹98.30 Cr | ₹81.10 Cr | +21.2% |
| Profit after tax | ₹76.60 Cr | ₹62.90 Cr | +21.8% |
| EBITDA margin | 38.6% | 36.3% | +2.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.